Our results are very similar to those observed with anti-CCP2 antibodies in this and other studies [42-44], but differ from those observed with anti-citrullinated vimentin antibodies, in which an association between clinical improvement and change in antibody titers was reported in early RA [40]. The gene discussed is AGBL2; the disease is rheumatoid arthritis.